Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
In this study, we present the clinicopathological features associated with PD-L1 protein and mRNA expression in a large Asian cohort of patients with non-small cell lung cancer (NSCLC) and assessed the prognostic implications of PD-L1 expression, particularly in early stage NSCLC. We retrospectively...
Main Authors: | Hyojin Kim, Hyun Jung Kwon, Soo Young Park, Youngmi Park, Eunhyang Park, Jin-Haeng Chung |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5983554?pdf=render |
Similar Items
-
Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
by: Yeon Bi Han, et al.
Published: (2019-03-01) -
Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis
by: Huarong Cai, et al.
Published: (2020-06-01) -
Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis
by: Hye Min Kim, et al.
Published: (2017-10-01) -
Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
by: Jing-Hua Li, et al.
Published: (2018-09-01) -
Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance
by: Hyein Ahn, et al.
Published: (2018-03-01)